Cartesian Therapeutics, Inc. - Common Stock - Mali Tablolar (NASDAQ:RNAC) | MetaTrader

Tam grafiği aç Full chart

Haberler

Mizuho, Cartesian Therapeutics için 40 dolarlık hedefi korudu

Cartesian Therapeutics hisse hedefi lansman zamanlaması nedeniyle 25 dolara düşürüldü

Bristol Myers Squibb: The CAR-T Giant The Market Is Undervaluing (NYSE:BMY)

Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates

Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?

Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Cartesian Therapeutics yönetim kurulu üyesi Murat Kalayoğlu 31 Mart’ta istifa edecek

BTIG, Cartesian Therapeutics için Al tavsiyesini yineledi

BTIG reiterates Buy on Cartesian Therapeutics stock, $44 target

Mizuho, Cartesian Therapeutics hissesi için tavsiyesini korudu

Mizuho reiterates Cartesian Therapeutics stock rating on trial progress

Kyverna Stock: The King Of The CAR-T Autoimmune Revolution (NASDAQ:KYTX)